Bispecifics in R/R MM: Key Data and Clinical Implications From ASH 2024 and Ongoing Trials
Panelists discuss how bispecific antibodies are reshaping the therapeutic approach in relapsed/refractory multiple myeloma (R/R MM), covering their mechanism of action, currently approved agents, and potential advantages. They explore how these therapies have transformed clinical decision-making, including optimal lines of therapy, patient selection, and best practices for integrating bispecifics into clinical practice.
Video content above is prompted by the following:
- Let's now turn our attention to another class of therapies: bispecific antibodies. With several now approved by the FDA and combination trials underway, let's now discuss the landscape of bispecific antibodies—optimal lines of therapy, patient selection, and best practices for integrating these agents into clinical practice.
- How are bispecific antibodies reshaping our therapeutic approach in relapsed/refractory multiple myeloma? Walk us through their mechanism of action, currently approved agents, potential advantages, and how these therapies have transformed your clinical decision-making.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
